Gemcitabine Plus FOLFIRI May Be Safe and Effective as First-Line Treatment of Metastatic Pancreatic Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the European Journal of Cancer, researchers have found that a sequential approach of alternating irinotecan, leucovorin, fluorouracil, and gemcitabine may be a safe and effective strategy for the treatment of patients with metastatic pancreatic adenocarcinoma.

For the phase 2 study, researchers sought to investigate fixed-dose rate gemcitabine alone or alternating with irinotecan, leucovorin, and fluorouracil as first-line treatment for patients with metastatic pancreatic cancer. Researchers enrolled 98 patients between October 2007 and March 2011.

Participants were randomly assigned 1:1 to receive fixed-dose rate gemcitabine alone or irinotecan, leucovorin, and fluorouracil alternating with fixed-dose rate gemcitabine as 2-month periods. All patients had a World Health Organization performance status of 0 or 1 and bilirubin levels <1.5 the upper limit of normal.

At 6 months, researchers observed a progression-free survival rate of 43.5% (95% CI, 28.6 - 58.4) in the alternating regimen group and 26.1% (95% CI, 12.9 - 39.3) in the gemcitabine alone group. The findings suggest that this alternating strategy may be a safe and effective approach to first-line treatment of patients with metastatic pancreatic adenocarcinoma.

Pancreatic Cancer: An Exocrine and Endocrine Disease
Alternating irinotecan, leucovorin, fluorouracil, and gemcitabine may be a safe and effective.
This study aims to find out whether a sequential approach alternating irinotecan, fluorouracil and gemcitabine may be effective and tolerable in patients with metastatic pancreatic cancer.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs